SCLX Stock Price, Chart, Stats & News
Scilex Holding Company (SCLX) does not currently pay a dividend.
SCLX chart
Fundamentals
Gross margin | 68.59% |
Operating margin | -652.37% |
Pretax margin | -828.52% |
Net margin | -931.21% |
Effective tax rate | -0.01% |
ROA | -136.23% |
ROE | 181.11% |
D/E | -0.38x |
Interest coverage ratio | -31.93x |
SCLX valuation
P/E | – |
P/S | 1.36x |
P/B | -0.42x |
P/CF | 3.12x |
P/FCF | 2.30x |
P/OCF | 3.12x |
PEG | 0.00x |
EV multiple | 0.04x |
About
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain.
Similar securities
Based on sector and market capitalization
